Phase II study of amrubicin combined with carboplatin for unresectable invasive thymoma or thymic carcinoma
Not Applicable
- Conditions
- Thymoma/Thymic carcinoma
- Registration Number
- JPRN-UMIN000002619
- Lead Sponsor
- Tohoku University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Severe co-morbidities 2. Symptomatic brain metastasis 3. Massive effusion that require drainage 4. Pregnant woman
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method